A study to investigate the safety, tolerability, and efficacy of AZD0120 in adults with Refractory SLE

Trial Identifier: D8313C00001
Sponsor: AstraZeneca
Start Date: April 2025
Primary Completion Date: May 2029
Study Completion Date: May 2029
Condition: Lupus

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, MD Bethesda, MD, US, 20892
US, New York Syracuse, New York, US, 13202-2240
US, NY New York, NY, US, 10032
US, WA Seattle, WA, US, 98195
US, WA Seattle, WA, US, 98104